查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1978846

消化性溃疡治疗市场：2026-2032年全球市场预测（依给药途径、品牌类型、剂型、药物类别、销售管道、最终用户和分销管道划分）

Peptic Ulcer Drugs Market by Route Of Administration, Brand Type, Dosage Form, Drug Class, Sales Channel, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，胃溃疡治疗市场价值将达到 49.9 亿美元，到 2026 年将成长至 52.6 亿美元，到 2032 年将达到 77 亿美元，复合年增长率为 6.39%。

主要市场统计数据
基准年 2025 49.9亿美元
预计年份：2026年 52.6亿美元
预测年份 2032 77亿美元
复合年增长率 (%) 6.39%

简要概述当前影响消化性溃疡治疗格局和相关人员决策的临床、商业性和供应方面趋势。

消化性溃疡的治疗仍然是胃肠病学实践的基石，其临床重点在于控制症状、促进黏膜癒合和预防併发症。抑酸药物的进步和临床通讯协定的改进改变了临床医生诊断和治疗消化性溃疡的方式，使许多治疗决策从住院治疗转移到门诊和居家照护护理。患者和医疗保健提供者现在受益于对幽门螺旋桿菌的作用、长期持续抑酸治疗的影响以及在慢性治疗中平衡疗效和安全性的更深入了解。

科学进步、监管审查和分销创新如何推动消化性溃疡治疗在整个护理路径中的策略重组。

在科学进步、监管重新评估和患者就医途径不断发展的推动下，消化性溃疡治疗的治疗和商业性格局正在经历变革性变化。科学方面，对胃酸功能和黏膜保护机制的深入理解，明确了何时以及如何应用强效抑酸疗法，从而促成​​了指南的修订和处方实践的改进。同时，真实世界安全性数据和药物安全监测的发现，加强了对长期治疗的审查，引入了更为谨慎的停药框架，优先考虑适当的治疗持续时间和监测，以及促进患者和医生之间协作决策的工具。

本研究评估了近期关税变化如何促使消化性溃疡药物的生产和分销进行供应链重组、近岸外包和全面商业策略。

近期影响医药原料和成品的关税措施和贸易政策调整，对整个产业的供应链经济和筹资策略带来了压力。某些进口药用活性成分和辅料关税的提高，迫使生产商重新评估其采购体系，许多公司正在权衡不断上涨的接收成本与供应商突然变更带来的营运风险之间的利弊。进口关税也可能影响下游决策，例如契约製造合作伙伴的选择、库存布局以及在多个司法管辖区维持分散式生产的可行性。

从给药途径、销售管道通路、品牌类型、剂型、最终用户、分销管道和药物类别等观点进行详细的观点，从而实现策略选择。

细分市场层面的区分揭示了临床应用、商业策略和营运要求的显着差异，这些差异影响着产品的开发、行销和交付方式。给药途径将情况分为口服疗法和肠外疗法。口服疗法适用于常规治疗和非处方药（OTC），而肠外疗法则用于急性住院治疗或无法耐受口服给药的患者。销售管道对市场准入提出了不同的要求。作为非处方药，其重点在于面向消费者的讯息、包装和零售分销；而处方药则需要与处方医生进行沟通、协商药物推广方案以及开展药物安全监测项目。

美洲、欧洲、中东和非洲以及亚太地区的监管、报销和供应链现实情况，是市场进入和商业化方法的差异化因素。

区域趋势对法律规范、报销标准和供应链结构产生深远影响，进而对策略规划产生重大影响。在美洲，监管机构和支付者强调循证药物清单、成本控制机制以及公私合作采购模式，这些模式旨在评估药物已证实的临床价值和成本效益。这种环境鼓励製药公司投资于稳健的临床项目、真实世界数据（REW）生成以及与支付方的合作策略，以在治疗获益和预算限制之间取得平衡。

决定製药公司、非专利生产商、契约製造生产商、经销商和服务合作伙伴竞争地位的策略行动和能力。

在消化性溃疡治疗领域运作的产业相关人员必须平衡创新、品质和规模，才能保持竞争力。大型跨国製药公司往往投资于广泛的临床开发项目、完善的药物安全监测系统以及支持品牌药和学名药的全球製造地。这些公司优先考虑监管多元化、策略联盟以及应对复杂竞标环境的能力，尤其是在医院采购和国家处方集发挥关键作用的领域。

加强供应韧性、监管应对力和全通路销售系统的实用策略，以在胃溃疡治疗领域保持竞争优势。

在瞬息万变的消化性溃疡治疗市场中，产业领导企业应优先考虑供应链韧性、监管灵活性和差异化的病人参与，以掌握机会并降低风险。加强供应商多元化策略，投资区域生产和双重采购安排，可以保障关键剂型的供应连续性，同时降低贸易中断和关税波动带来的风险。此外，企业还应透过实施供应商监控的高级分析、增强批次级可追溯性以及主动进行污染风险评估，实现品管系统的现代化，从而维护产品完整性并确保符合监管要求。

严谨的混合方法研究框架，结合对专家的初步访谈、对法规和临床方面的二次分析以及供应链映射，为检验的研究结果提供了支持。

本分析采用多方面研究方法，结合一手访谈、二手文献综述以及结构化的供应链和监管检验，以确保获得平衡且经得起验证的见解。我们咨询了临床实践、药品生产、分销和采购领域的专家，以收集关于治疗管理、品质和生产挑战以及商业性需求的多元观点。此外，我们还使用了包括同侪审查的临床文献、监管建议、行业指导文件和公开文件在内的二级资讯来源，以提供权威的、基于证据的临床和政策观察。

作为胃溃疡治疗领域持续表现的支柱，我们强调韧性、证据产生以及基于以客户为中心的执行的结论整合。

消化性溃疡治疗领域的特征是临床需求持续存在、监管不断加强以及商业性模式不断演变，所有这些因素都要求行业相关人员采取适应性策略。在临床方面，有效抑制胃酸分泌和控制感染疾病仍然是重中之重，而安全性考量和患者偏好正在改变长期用药的实践方式。在营运方面，供应链的稳健性和合规性是影响市场持续性和品牌声誉的关键因素。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：消化性溃疡治疗市场：依给药途径划分

  • 口服
  • 肠外

第九章：按品牌类型分類的消化性溃疡治疗药物市场

  • 品牌商品
  • 非专利的

第十章 按剂型分類的消化性溃疡治疗药物市场分布

  • 胶囊
  • 注射药物
  • 药片

第十一章 消化性溃疡治疗市场：依药物类别划分

  • H2受体拮抗剂
    • 西咪替丁
    • 法莫替丁
    • 尼扎替丁
    • 雷尼替丁
  • 质子帮浦阻断剂
    • Esomeprazole
    • 兰索拉唑
    • 奥美拉唑
    • 泮托拉唑
    • Rabeprazole

第十二章：消化性溃疡治疗市场：依销售管道划分

  • 非处方药
  • 处方药

第十三章：消化性溃疡治疗市场：依最终用户划分

  • 居家医疗
  • 医院
  • 门诊部

第十四章 消化性溃疡治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十五章：消化性溃疡治疗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：消化性溃疡治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 消化性溃疡治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国消化性溃疡治疗市场

第十九章：中国消化性溃疡治疗市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cadila Healthcare Ltd.
  • Century Pharmaceuticals Ltd.
  • Daewoong Pharmaceutical Co. LTD.
  • Dr. Reddy's Laboratories Ltd
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Medopharm Pvt Ltd
  • Merck KGaA
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Pharmanova India Drugs Pvt. Ltd.
  • Redhill Biopharma Ltd
  • Rosemont Pharmaceuticals Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-2A0283E25692

The Peptic Ulcer Drugs Market was valued at USD 4.99 billion in 2025 and is projected to grow to USD 5.26 billion in 2026, with a CAGR of 6.39%, reaching USD 7.70 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.99 billion
Estimated Year [2026] USD 5.26 billion
Forecast Year [2032] USD 7.70 billion
CAGR (%) 6.39%

A concise orientation to current clinical, commercial, and supply-side dynamics shaping the peptic ulcer therapeutics environment and stakeholder decisions

Peptic ulcer therapeutics remain a cornerstone of gastroenterology practice, with a clinical focus that spans symptom control, mucosal healing, and complication prevention. Advances in acid suppression pharmacology and refined clinical pathways have reshaped how clinicians diagnose and manage peptic ulcer disease, shifting many care decisions from inpatient settings to ambulatory and home care environments. Patients and providers now benefit from a deeper understanding of Helicobacter pylori's role, the long-term implications of sustained acid suppression, and the need to balance efficacy with safety in chronic therapy.

Clinically, proton pump inhibitors have become the dominant modality for achieving profound and durable acid suppression, while H2 receptor antagonists continue to play a supporting role in selected scenarios and as short-term therapies. The therapeutic landscape has been influenced by regulatory actions, product recalls, and evolving OTC access models, which together affect prescriber behavior and patient self-management. Concurrently, the supply chain that brings these medicines from API production through finished-dose manufacturing to distribution and point-of-care has become more complex, influenced by global sourcing, regulatory harmonization, and evolving reimbursement practices.

This executive summary synthesizes current dynamics affecting the peptic ulcer drugs arena, emphasizing the interplay between clinical evidence, regulatory developments, commercialization channels, and operational realities. The aim is to provide decision-makers with a clear, actionable perspective that integrates therapeutic performance considerations with commercial and supply-side realities, supporting informed strategy development across product portfolios, distribution networks, and stakeholder engagement plans.

How scientific advances, regulatory scrutiny, and distribution innovation are driving a strategic reconfiguration of peptic ulcer therapeutics across care pathways

The therapeutic and commercial landscape for peptic ulcer drugs is undergoing transformative shifts driven by scientific advances, regulatory recalibration, and changes in patient access pathways. On the scientific front, improved mechanistic understanding of gastric acid physiology and mucosal protection has refined when and how aggressive acid suppression is deployed, prompting guideline revisions and more nuanced prescribing practices. At the same time, real-world safety data and pharmacovigilance findings have increased scrutiny of long-term therapy, leading to more deliberate deprescribing frameworks and shared decision-making tools that prioritize appropriate duration and monitoring.

Regulatory and quality challenges have also catalyzed change. Manufactured product integrity, API sourcing practices, and contamination incidents have led to tighter oversight and an emphasis on supplier transparency. These pressures are accelerating industry adoption of enhanced quality assurance measures and dual-sourcing strategies to protect continuity of supply. Commercially, the lines between prescription and over-the-counter access have blurred, expanding patient choice while forcing manufacturers and distributors to adapt marketing, packaging, and patient education efforts to a more retail-oriented context.

Lastly, digital and distribution innovations are redefining patient touchpoints. Telemedicine follow-ups, remote pharmacy services, and the growth of online pharmacy platforms have shifted where and how patients obtain therapies, creating opportunities to embed adherence support and clinical decision aids into the care continuum. Together, these shifts are compelling incumbent players to revisit product positioning, invest in quality and regulatory compliance, and design omnichannel strategies that reflect new patient journeys and payer priorities.

Assessing how recent tariff shifts are prompting supply chain redesign, nearshoring, and integrated commercial strategies across peptic ulcer drug production and distribution

Recent tariff actions and trade policy adjustments affecting pharmaceutical inputs and finished products are exerting pressure on supply chain economics and sourcing strategies across the industry. Increased duties on certain imported active pharmaceutical ingredients and excipients have prompted manufacturers to reassess their procurement footprints, with many evaluating the trade-offs between higher landed costs and the operational risks of rapid supplier substitution. Import tariffs can also influence downstream decisions about contract manufacturing partner selection, inventory positioning, and the viability of maintaining decentralized production across multiple jurisdictions.

From an operational viewpoint, tariffs have accelerated the adoption of nearshoring and regional manufacturing strategies aimed at mitigating exposure to cross-border duties and transport volatility. These shifts often require capital investment in manufacturing capacity and quality systems, and they can extend lead times for new product introductions. For companies that rely heavily on complex global supply chains, tariffs have encouraged the development of more robust scenario planning and stress-testing of supplier ecosystems, as well as stronger contractual protections around pricing and supply continuity.

On the commercial side, tariff-driven cost pressures are influencing pricing strategies, negotiations with payers, and channel incentives. Payers and procurement teams are increasingly attentive to total cost of ownership, which includes logistics, tariff burden, and regulatory compliance overhead. In response, manufacturers and distributors are exploring value-based contracting, bundled procurement arrangements, and collaborative sourcing partnerships to preserve access while managing margin compression. These adaptive measures underscore the need for integrated commercial and supply chain planning to ensure that tariff impacts are anticipated, managed, and, where possible, converted into competitive advantage.

Deep segmentation perspectives that connect administration routes, sales channels, brand types, dosage forms, end users, distribution channels, and drug classes to strategic choices

Segment-level distinctions reveal meaningful differences in clinical use, commercial strategy, and operational requirements that shape how products are developed, marketed, and delivered. Route of administration divides the landscape between oral therapies, which dominate routine management and OTC access, and parenteral options that are reserved for acute hospital care or patients unable to tolerate oral dosing. Sales channels create divergent go-to-market imperatives: over-the-counter availability prioritizes consumer-facing messaging, packaging, and retail distribution, while prescription drugs require prescriber engagement, formulary access negotiations, and pharmacovigilance programs.

Brand type introduces another axis of strategic differentiation. Branded products often compete on differentiation, clinical evidence, and service offerings such as patient support programs, whereas generics compete primarily on cost competitiveness, manufacturing scale, and distribution efficiency. Dosage form matters operationally and commercially; capsules, injections, and tablets each entail distinct manufacturing processes, stability considerations, and patient acceptance dynamics that influence product lifecycle planning. End-user segmentation further informs deployment choices, with home care favoring convenience, simplified regimens, and patient education tools, hospitals requiring injectable and IV-compatible formulations alongside robust supply logistics, and outpatient clinics balancing cost, adherence, and ease of administration.

Distribution channel nuances are equally consequential. Hospital pharmacies maintain tight integration with inpatient workflows and clinical governance, online pharmacies prioritize digital engagement, compliance, and last-mile logistics, and retail pharmacies emphasize shelf placement, promotional activity, and point-of-sale counseling. Finally, drug class characteristics underpin both clinical and commercial strategy. H2 receptor antagonists and proton pump inhibitors differ in onset, potency, and duration of effect, with subclasses and individual molecules such as cimetidine, famotidine, nizatidine, ranitidine, esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole exhibiting distinct pharmacokinetic and safety profiles that inform prescribing guidance, labeling strategies, and competitor positioning. Understanding these layered segmentation dynamics is essential for aligning R&D priorities, manufacturing investments, and market access efforts with the realities of patient care and payer expectations.

Regional regulatory, reimbursement, and supply chain realities across the Americas, EMEA, and Asia-Pacific that shape differentiated market entry and commercialization approaches

Regional dynamics shape regulatory frameworks, reimbursement norms, and supply chain architectures in ways that materially affect strategic planning. In the Americas, regulatory authorities and payer systems emphasize evidence-based formularies, cost containment mechanisms, and a mix of public and private procurement approaches that reward demonstrated clinical value and cost-effectiveness. This environment incentivizes manufacturers to invest in robust clinical programs, real-world evidence generation, and payer engagement strategies that reconcile therapeutic benefits with budgetary constraints.

In Europe, the Middle East, and Africa, heterogeneity in regulatory capacity and reimbursement policies requires nuanced market entry strategies. European markets often feature centralized or harmonized approval pathways coupled with stringent HTA processes, while markets in the Middle East and Africa present a mosaic of procurement models, varying levels of clinical infrastructure, and differing demands for local regulatory documentation. Manufacturers and distributors must therefore tailor their licensing, pricing, and supply chain approaches to reflect local regulatory expectations and procurement behaviors.

The Asia-Pacific region presents a blend of rapid innovation adoption in some high-income markets and large-volume, cost-sensitive demand in emerging economies. Policymakers in the region have increasingly prioritized local manufacturing capacity and pharmaceutical self-sufficiency, which affects foreign manufacturers' market access strategies and partnership models. Across all regions, digital distribution and telehealth adoption are changing patient access patterns, necessitating region-specific digital engagement and e-commerce strategies to capture new customer journeys and preserve adherence outcomes.

Strategic behaviors and capabilities of manufacturers, generics producers, contract manufacturers, distributors, and service partners that determine competitive positioning

Industry players operating in the peptic ulcer therapeutics space must balance innovation, quality, and scale to remain competitive. Large multinational pharmaceutical firms tend to invest in broad clinical development programs, extensive pharmacovigilance infrastructure, and global manufacturing footprints that support both branded and generic portfolios. These firms prioritize regulatory diversification, strategic alliances, and the ability to navigate complex tendering environments, especially where hospital procurement and national formularies play a pivotal role.

Generic manufacturers and specialty producers focus on manufacturing excellence and cost leadership, leveraging high-volume production and process optimization to compete on price and availability. Contract manufacturing organizations and API suppliers are central to maintaining continuity of supply, particularly as firms pursue multi-sourcing strategies to mitigate quality and geopolitical risks. Distributors and pharmacy chains, including online platforms, play a critical role in shaping patient access and adherence through integrated logistics, patient education initiatives, and digital engagement tools.

Across this ecosystem, service providers that deliver regulatory support, quality assurance auditing, and cold chain logistics add strategic value by reducing time-to-market and lowering the operational burden on manufacturers. Partnerships between commercial organizations and clinical stakeholders-such as hospitals and specialty clinics-are increasingly common, as these collaborations facilitate formulary access, real-world evidence collection, and post-launch surveillance activities that reinforce product positioning and reimbursement negotiations.

Actionable strategies for strengthening supply resilience, regulatory readiness, and omnichannel commercialization to sustain competitive advantage in peptic ulcer therapeutics

Industry leaders should prioritize supply chain resilience, regulatory agility, and differentiated patient engagement to capture opportunities and mitigate risks in the evolving peptic ulcer therapeutics landscape. Strengthening supplier diversification strategies and investing in regional manufacturing or dual-sourcing arrangements will reduce vulnerability to trade disruptions and tariff volatility while supporting continuity of supply for critical dosage forms. Concurrently, companies should modernize quality oversight by implementing advanced analytics for supplier monitoring, enhanced lot-level traceability, and proactive contamination risk assessment to preserve product integrity and regulatory compliance.

On commercialization, organizations must design tailored omnichannel strategies that reflect the distinct dynamics of over-the-counter and prescription markets. This includes digital outreach and adherence support for home care patients, targeted clinical engagement for hospital and outpatient clinic prescribers, and optimized retail and online distribution models that address convenience and compliance. Value demonstration efforts should focus on real-world effectiveness, safety profiles, and total cost of care implications to align with payer priorities and to support favorable formulary positioning.

Finally, leaders should embed regulatory intelligence and scenario planning into strategic decision-making. Anticipatory regulatory mapping, early dialogue with authorities, and investment in post-market surveillance infrastructure will accelerate responsive labeling and supply adjustments when safety signals or policy shifts occur. By integrating operational resilience, commercial precision, and regulatory foresight, companies can not only withstand market disruptions but also create defensible competitive advantages.

A rigorous mixed-method research framework combining primary expert engagement, secondary regulatory and clinical analysis, and supply chain mapping to underpin validated insights

This analysis was developed using a multi-method research approach that combined primary interviews, secondary literature review, and structured supply chain and regulatory analysis to ensure balanced and validated insights. Subject-matter experts from clinical practice, pharmaceutical manufacturing, distribution, and procurement were consulted to capture diverse perspectives on therapeutic management, quality and manufacturing challenges, and commercial imperatives. Secondary sources included peer-reviewed clinical literature, regulatory advisories, industry guidance documents, and public filings to ground clinical and policy observations in authoritative evidence.

Supply chain assessments relied on supplier mapping, review of public customs and trade data, and analysis of logistics pathways to identify common vulnerabilities and mitigation strategies. Regulatory analysis drew on public agency communications, safety alerts, and guidance documents to track evolving compliance expectations and reporting obligations. Throughout the research process, findings were triangulated across independent sources to validate conclusions and to expose areas of uncertainty.

Limitations of the methodology include reliance on publicly available regulatory communications and expert interviews that may not capture proprietary commercial arrangements or the most recent confidential supplier negotiations. To mitigate these constraints, the study emphasizes transparent assumptions, cites regulatory positions where applicable, and recommends follow-up primary research for organizations seeking deep-dive, proprietary intelligence or custom scenario modeling.

Concluding synthesis emphasizing resilience, evidence generation, and customer-centric execution as pillars for sustained performance in peptic ulcer therapeutics

The peptic ulcer therapeutics arena is characterized by enduring clinical needs, ongoing regulatory vigilance, and evolving commercial modalities that together demand adaptive strategies from industry participants. Clinically, effective acid suppression and the integration of infection management remain priority imperatives, while safety considerations and patient preference are reshaping long-term use. Operationally, supply chain robustness and regulatory compliance are central determinants of market continuity and brand reputation.

Commercial success will increasingly depend on the ability to align product portfolios with differentiated patient journeys, to demonstrate real-world value to payers, and to deploy flexible manufacturing and sourcing models that withstand geopolitical and trade-related shocks. Organizations that proactively invest in quality assurance, omnichannel patient engagement, and regulatory intelligence will be best positioned to translate clinical efficacy into sustainable market access and commercial performance. These conclusions point toward a strategic roadmap built on resilience, evidence, and customer-centric execution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peptic Ulcer Drugs Market, by Route Of Administration

  • 8.1. Oral
  • 8.2. Parenteral

9. Peptic Ulcer Drugs Market, by Brand Type

  • 9.1. Branded
  • 9.2. Generic

10. Peptic Ulcer Drugs Market, by Dosage Form

  • 10.1. Capsule
  • 10.2. Injection
  • 10.3. Tablet

11. Peptic Ulcer Drugs Market, by Drug Class

  • 11.1. H2 Receptor Antagonists
    • 11.1.1. Cimetidine
    • 11.1.2. Famotidine
    • 11.1.3. Nizatidine
    • 11.1.4. Ranitidine
  • 11.2. Proton Pump Inhibitors
    • 11.2.1. Esomeprazole
    • 11.2.2. Lansoprazole
    • 11.2.3. Omeprazole
    • 11.2.4. Pantoprazole
    • 11.2.5. Rabeprazole

12. Peptic Ulcer Drugs Market, by Sales Channel

  • 12.1. Over The Counter
  • 12.2. Prescription Drugs

13. Peptic Ulcer Drugs Market, by End User

  • 13.1. Home Care
  • 13.2. Hospitals
  • 13.3. Outpatient Clinics

14. Peptic Ulcer Drugs Market, by Distribution Channel

  • 14.1. Hospital Pharmacies
  • 14.2. Online Pharmacies
  • 14.3. Retail Pharmacies

15. Peptic Ulcer Drugs Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Peptic Ulcer Drugs Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Peptic Ulcer Drugs Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Peptic Ulcer Drugs Market

19. China Peptic Ulcer Drugs Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Abbott Laboratories
  • 20.6. AbbVie Inc.
  • 20.7. AstraZeneca PLC
  • 20.8. Boehringer Ingelheim International GmbH
  • 20.9. Cadila Healthcare Ltd.
  • 20.10. Century Pharmaceuticals Ltd.
  • 20.11. Daewoong Pharmaceutical Co. LTD.
  • 20.12. Dr. Reddy's Laboratories Ltd
  • 20.13. Eisai Co. Ltd.
  • 20.14. F. Hoffmann-La Roche Ltd.
  • 20.15. GlaxoSmithKline PLC
  • 20.16. Hikma Pharmaceuticals PLC
  • 20.17. Medopharm Pvt Ltd
  • 20.18. Merck KGaA
  • 20.19. Mylan N.V.
  • 20.20. Novartis AG
  • 20.21. Pfizer Inc.
  • 20.22. Pharmanova India Drugs Pvt. Ltd.
  • 20.23. Redhill Biopharma Ltd
  • 20.24. Rosemont Pharmaceuticals Limited
  • 20.25. Takeda Pharmaceutical Company Limited
  • 20.26. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PEPTIC ULCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PEPTIC ULCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA PEPTIC ULCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 185. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 186. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 188. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 215. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 217. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 218. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 225. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 226. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 227. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 228. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA PEPTIC ULCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)